Please login to the form below
axicabtagene ciloleucel
This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.
Kite’s CAR-T therapies recommended by NICE for certain blood cancers
Kite's Yescarta (axicabtagene ciloleucel) has been recommended for adults with diffuse large B‑cell lymphoma (DLBCL) that returns within a year of, or is resistant to, first-line chemoimmunotherapy.
Latest news
-
Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
Gilead Science and Kite, a Gilead company, have announced that the National Institute for Health and Care Excellence (NICE) has recommended Yescarta (axicabtagene ciloleucel) to treat certain forms of lymphoma.
-
Kite’s CAR-T therapy Yescarta granted EC approval in second-line lymphoma
Kite, a Gilead company, has announced that the European Commission (EC) has granted approval for use of Yescarta (axicabtagene ciloleucel) as a second-line treatment in adult patients with diffuse large
-
Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury
Yescarta (axicabtagene ciloleucel) reached $175m in relapsed/refractory large B-cell lymphoma and relapsed/refractory indolent follicular lymphoma in both the US and Europe.
-
BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
Kite has already seen success with its own CAR T treatments, which includes Tecartus (brexucabtagene autoleucel) and Yescarta (axicabtagene ciloleucel).
-
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
The top-line results come from the phase 3 ZUMA-7 trial, which is investigating Yescarta (axicabtagene ciloleucel) compared to standard of care (SOC) in second-line LBCL.
More from news
Approximately 1 fully matching, plus 51 partially matching documents found.
Latest Intelligence
-
The European Medicines Agency: PRIME’d for access?
Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
-
Deal Watch January 2017
Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn
- Landscape review reveals £1.1bn of UK funding for rare diseases
- Cancer Research UK partners with French cancer institute
- New diagnosis pathway has been launched to mark European Myeloma Day
- Impacting Lives with Rare Disease Education
- Sandoz biosimilar receives EC approval to treat MS
No results were found
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
